{"id":"high-dose-inactivated-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site soreness"},{"rate":"10-20","effect":"Myalgia"},{"rate":"10-20","effect":"Fatigue"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated (killed) influenza virus particles at higher antigen concentrations than standard-dose vaccines, which triggers more robust activation of B cells and T cells. This enhanced immunogenicity is intended to provide superior protection against influenza infection, particularly in older adults and immunocompromised populations who may have diminished responses to standard-dose vaccines.","oneSentence":"A high-dose inactivated influenza vaccine stimulates a stronger immune response by delivering increased antigen content to enhance antibody production and cellular immunity against influenza viruses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:41.625Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention in adults aged 65 years and older"},{"name":"Influenza prevention in immunocompromised populations"}]},"trialDetails":[{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT04613206","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-01-11","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":396},{"nctId":"NCT05215327","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-11-08","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":270},{"nctId":"NCT06641180","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-04","conditions":"Influenza","enrollment":1180},{"nctId":"NCT06824519","phase":"PHASE1, PHASE2","title":"Clinical Trials of Quadrivalent Influenza Vaccine","status":"RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2025-05-08","conditions":"Influenza, Human","enrollment":620},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT07192458","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-09-17","conditions":"Immunization; Infection|Transplantation Infection|Influenza, Influenza","enrollment":60},{"nctId":"NCT06125691","phase":"PHASE1","title":"Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-01-22","conditions":"Influenza, Human","enrollment":139},{"nctId":"NCT04498832","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-21","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":2100},{"nctId":"NCT04137887","phase":"PHASE3","title":"Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-04","conditions":"Influenza (Healthy Volunteers)","enrollment":33096},{"nctId":"NCT04101838","phase":"PHASE4","title":"B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-04-01","conditions":"Influenza","enrollment":50},{"nctId":"NCT04969276","phase":"PHASE2","title":"Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-07-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":306},{"nctId":"NCT04024228","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-28","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":1539},{"nctId":"NCT05663463","phase":"NA","title":"Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-09-11","conditions":"Solid Organ Transplant","enrollment":74},{"nctId":"NCT04896086","phase":"PHASE1","title":"First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-24","conditions":"Influenza, Seasonal Influenza","enrollment":63},{"nctId":"NCT06695117","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-19","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT06059456","phase":"","title":"Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-10-02","conditions":"Influenza Immunization (Healthy Volunteers)","enrollment":2078},{"nctId":"NCT05947071","phase":"PHASE2","title":"High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-26","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":312},{"nctId":"NCT05624606","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-28","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT03179761","phase":"PHASE2","title":"High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2017-10-09","conditions":"Hematopoietic Cell Transplantation","enrollment":124},{"nctId":"NCT02936180","phase":"PHASE4","title":"Standard Versus High Dose Inactivated Influenza Vaccine in RA","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-10","conditions":"Rheumatoid Arthritis","enrollment":279},{"nctId":"NCT05007041","phase":"PHASE4","title":"Simultaneous RZV and aIIV4 Vaccination","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-09-21","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":267},{"nctId":"NCT05568979","phase":"","title":"Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-10-06","conditions":"Influenza (Healthy Volunteers)","enrollment":1001},{"nctId":"NCT05409612","phase":"PHASE3","title":"Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-11-07","conditions":"Morbid Obesity, Severe Obesity","enrollment":206},{"nctId":"NCT06208683","phase":"PHASE4","title":"The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-11-04","conditions":"Mumps, Influenza","enrollment":400},{"nctId":"NCT05642078","phase":"PHASE3","title":"Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2023-02-18","conditions":"Prevention of Influenza","enrollment":2550},{"nctId":"NCT03330132","phase":"PHASE4","title":"Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2017-10-07","conditions":"Influenza, Human","enrollment":1861},{"nctId":"NCT06029933","phase":"","title":"Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years","status":"RECRUITING","sponsor":"Kaiser Permanente","startDate":"2023-08-17","conditions":"Influenza, Community-acquired Pneumonia, Cardiovascular Events","enrollment":960000},{"nctId":"NCT05996549","phase":"PHASE4","title":"Cost-effectiveness of the Influenza Vaccination","status":"UNKNOWN","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-09-29","conditions":"Influenza Vaccine, Cost-Effectiveness, Vaccination","enrollment":2567},{"nctId":"NCT03603509","phase":"PHASE4","title":"Gene Signatures of Influenza Vaccine Responses in Older Adults","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-08-27","conditions":"Influenza","enrollment":241},{"nctId":"NCT05078060","phase":"","title":"Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-10-12","conditions":"Influenza (Healthy Volunteers)","enrollment":1804},{"nctId":"NCT01808456","phase":"PHASE4","title":"Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.","status":"COMPLETED","sponsor":"Inova Health Care Services","startDate":"2013-10","conditions":"Influenza, Human, Transplantation Infection","enrollment":62},{"nctId":"NCT04077424","phase":"PHASE4","title":"Senescent Immunity in Elders and Vaccine Responses (SILVER)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-10-21","conditions":"Flu Vaccine","enrollment":10},{"nctId":"NCT03698279","phase":"PHASE2","title":"Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-09","conditions":"Influenza","enrollment":665},{"nctId":"NCT00908687","phase":"PHASE2","title":"A/H5N1/LT Dose Ranging Study","status":"COMPLETED","sponsor":"Intercell USA, Inc.","startDate":"2009-05","conditions":"Pandemic Influenza","enrollment":500},{"nctId":"NCT03738241","phase":"PHASE2","title":"2017 A/H7N9 IIV Revaccination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-18","conditions":"Avian Influenza, Influenza Immunisation","enrollment":304},{"nctId":"NCT03183908","phase":"PHASE4","title":"FLUAD® vs. Fluzone® High-Dose Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-08-28","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":757},{"nctId":"NCT03699839","phase":"PHASE2, PHASE3","title":"Reducing the Burden of Influenza After Solid-Organ Transplantation","status":"COMPLETED","sponsor":"Oriol Manuel","startDate":"2018-10-26","conditions":"Influenza, Organ Transplantation","enrollment":619},{"nctId":"NCT03926416","phase":"PHASE1","title":"Safety Study of Live Attenuated Influenza Vaccine, CodaVax","status":"COMPLETED","sponsor":"Codagenix, Inc","startDate":"2017-02-21","conditions":"Influenza","enrollment":125},{"nctId":"NCT00971906","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Pandemic Influenza","enrollment":660},{"nctId":"NCT02500680","phase":"PHASE1","title":"The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)","status":"UNKNOWN","sponsor":"Nova Immunotherapeutics Limited","startDate":"2015-07","conditions":"Influenza, Human","enrollment":102},{"nctId":"NCT01928472","phase":"PHASE1","title":"Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-08","conditions":"H7N9 Influenza","enrollment":402},{"nctId":"NCT01216332","phase":"PHASE1","title":"Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2010-10","conditions":"Pediatric Patients With Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT00170482","phase":"","title":"Elderly Influenza Vaccine Immunogenicity Substudy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-04-25","conditions":"Influenza","enrollment":60},{"nctId":"NCT02263040","phase":"PHASE1, PHASE2","title":"A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2014-10","conditions":"Influenza","enrollment":170},{"nctId":"NCT01945268","phase":"PHASE4","title":"Influenza Vaccine To Prevent Adverse Vascular Events:Pilot","status":"COMPLETED","sponsor":"McMaster University","startDate":"2015-04","conditions":"Heart Failure","enrollment":107},{"nctId":"NCT02762851","phase":"PHASE4","title":"Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE)","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2016-06","conditions":"Heart Failure, Influenza","enrollment":5000},{"nctId":"NCT01924169","phase":"PHASE2","title":"Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-11-24","conditions":"Hematologic Disorder","enrollment":3},{"nctId":"NCT02553343","phase":"PHASE2","title":"A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-09","conditions":"Influenza","enrollment":792},{"nctId":"NCT01685372","phase":"PHASE2","title":"Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2012-09","conditions":"Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV)","enrollment":16},{"nctId":"NCT03022396","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Influenza","enrollment":82},{"nctId":"NCT03022422","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011","status":"COMPLETED","sponsor":"Stanford University","startDate":"2011-09","conditions":"Influenza","enrollment":63},{"nctId":"NCT01827462","phase":"PHASE4","title":"Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2007-10","conditions":"Influenza","enrollment":136},{"nctId":"NCT01654224","phase":"PHASE4","title":"Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2011-11","conditions":"Influenza","enrollment":205},{"nctId":"NCT03022435","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012","status":"COMPLETED","sponsor":"Stanford University","startDate":"2012-10","conditions":"Influenza","enrollment":22},{"nctId":"NCT00680069","phase":"PHASE1, PHASE2","title":"H5N1 (Clade 2) Vaccination of Adults and Elderly","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-11","conditions":"Influenza","enrollment":517},{"nctId":"NCT00970177","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Pandemic Influenza","enrollment":812},{"nctId":"NCT00971100","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Pandemic Influenza","enrollment":752},{"nctId":"NCT01000207","phase":"PHASE2, PHASE3","title":"Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-10","conditions":"Swine-Origin Influenza A H1N1 Virus","enrollment":123},{"nctId":"NCT00996138","phase":"PHASE2, PHASE3","title":"Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-09","conditions":"Influenza","enrollment":200},{"nctId":"NCT02436928","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2015-04","conditions":"H7N9 Influenza Vaccine","enrollment":200},{"nctId":"NCT01525004","phase":"PHASE1","title":"Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2011-09","conditions":"Pediatric Solid Organ Transplant Patients","enrollment":38},{"nctId":"NCT00551031","phase":"PHASE2","title":"Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Influenza, Myxovirus Infection","enrollment":2098},{"nctId":"NCT01258595","phase":"PHASE2","title":"A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-11","conditions":"Influenza","enrollment":300},{"nctId":"NCT00848848","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2008-10","conditions":"Influenza","enrollment":450},{"nctId":"NCT00391053","phase":"PHASE3","title":"Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-10","conditions":"Orthomyxoviridae Infection, Influenza, Myxovirus Infection","enrollment":3851},{"nctId":"NCT00766285","phase":"PHASE2","title":"High Dose Influenza in Immunosuppressed Subjects","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Influenza","enrollment":""},{"nctId":"NCT01427309","phase":"PHASE4","title":"A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09","conditions":"Influenza","enrollment":31989},{"nctId":"NCT01776541","phase":"PHASE2","title":"Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-01","conditions":"Pandemic H5N1 Influenza","enrollment":979},{"nctId":"NCT01436370","phase":"PHASE2","title":"TIV and High Dose TIV in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-10","conditions":"Influenza","enrollment":102},{"nctId":"NCT00115531","phase":"PHASE2","title":"Eldery High Dose TIV 2005","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-04","conditions":"Influenza","enrollment":414},{"nctId":"NCT01709019","phase":"PHASE1","title":"RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly","status":"COMPLETED","sponsor":"Novavax","startDate":"2012-10","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":220},{"nctId":"NCT01089660","phase":"PHASE2","title":"A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-03","conditions":"Influenza, Swine-origin A/H1N1 Influenza","enrollment":202},{"nctId":"NCT01691339","phase":"PHASE4","title":"Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-09","conditions":"Influenza","enrollment":200},{"nctId":"NCT01675284","phase":"PHASE1","title":"A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine","status":"COMPLETED","sponsor":"Medigen Biotechnology Corporation","startDate":"2012-08","conditions":"Bird Flu, Avian Influenza, Influenza A(H5N1)","enrollment":36},{"nctId":"NCT01430819","phase":"PHASE4","title":"Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09","conditions":"Influenza","enrollment":300},{"nctId":"NCT00439335","phase":"PHASE1, PHASE2","title":"Higher Dose Intradermal H5 Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-03","conditions":"Influenza","enrollment":227},{"nctId":"NCT01215734","phase":"PHASE1","title":"Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2010-10","conditions":"Adult Stem Cell Hematopoetic Transplant","enrollment":44},{"nctId":"NCT00845429","phase":"PHASE2","title":"Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Influenza, Orthomyxoviruses, Myxovirus Infection","enrollment":729},{"nctId":"NCT00976027","phase":"PHASE3","title":"Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older","status":"TERMINATED","sponsor":"Sanofi","startDate":"2009-09","conditions":"Influenza","enrollment":9172},{"nctId":"NCT00532792","phase":"PHASE1","title":"A/H5N1 Dose Ranging Study With Adjuvant Patch","status":"COMPLETED","sponsor":"Intercell USA, Inc.","startDate":"2007-08","conditions":"Pandemic Influenza","enrollment":501},{"nctId":"NCT00971542","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-09","conditions":"Pandemic Influenza","enrollment":778},{"nctId":"NCT01201902","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2009-10","conditions":"Influenza Infection","enrollment":592}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"High Dose Inactivated Influenza Vaccine","genericName":"High Dose Inactivated Influenza Vaccine","companyName":"University of Pittsburgh","companyId":"university-of-pittsburgh","modality":"Biologic","firstApprovalDate":"","aiSummary":"A high-dose inactivated influenza vaccine stimulates a stronger immune response by delivering increased antigen content to enhance antibody production and cellular immunity against influenza viruses. Used for Influenza prevention in adults aged 65 years and older, Influenza prevention in immunocompromised populations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}